Pompe Disease Therapeutic Pipeline Analysis | Insights into the Latest Regulatory Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Companies

August 12 22:40 2022
Pompe Disease Therapeutic Pipeline Analysis | Insights into the Latest Regulatory Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight, the rise in the incidence of Pompe Disease (PD), ongoing Research and Development (R&D) activities, along with the expected launch of emerging therapies, is expected to boost the Pompe Disease Therapeutic Market growth in the coming years.

“Pompe Disease Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pompe Disease Market.

The Pompe Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Pompe Disease Pipeline Analysis

Pompe Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pompe Disease with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Pompe Disease Treatment.

  • Pompe Disease key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Pompe Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pompe Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight

Pompe Disease Therapeutics Landscape

Alglucosidase alfa (Myozyme/Lumizyme, Sanofi Genzyme) enzyme replacement therapy (ERT) using recombinant human GAA (rhGAA), is currently the only approved treatment for Pompe disease. Although the ERT appears to slow disease progression but has not been shown to halt or reverse disease for the majority of patients, and thus; there remains a significant gap in treatment outcome.

To fulfill the unmet need, companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years.

Some of the key players in the Pompe Disease (PD) market include:

  • Sanofi

  • Actus

  • Amicus

  • Roche 

  • Audentes Therapeutics

  • Valerion Therapeutics

And others 

Pompe Disease Therapies covered in the report include –

  • Avalglucosidase alfa

  • AT-GAA

  • ACTUS-101

  • VAL-1221

  • AT845

  • SPK-3006

And many others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Pompe Disease Current Treatment Patterns

4. Pompe Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Pompe Disease Late Stage Products (Phase-III)

7. Pompe Disease Mid-Stage Products (Phase-II)

8. Pompe Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pompe Disease Discontinued Products

13. Pompe Disease Product Profiles

14. Key Companies in the Pompe Disease Market

15. Key Products in the Pompe Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Pompe Disease Unmet Needs

18. Pompe Disease Future Perspectives

19. Pompe Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Report by DelveInsight

Spinal Fusion Devices Market
“Spinal Fusion Devices Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Spinal Fusion Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Spinal Fusion Devices market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/